Rodney A. Bednar, Ph.D.

Pennsylvania Drug Discovery Institute 
 Merck Research Laboratories, West Point, Pennsylvania, Lansdale, PA, United States 
 Stony Brook University, Stony Brook, NY, United States 
Drug Discovery, Enzymology
"Rodney Bednar"
Mean distance: 7.69
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Garner R, Gopalakrishnan S, McCauley JA, et al. (2015) Preclinical pharmacology and pharmacokinetics of CERC-301, a GluN2B-selective N-methyl-D-aspartate receptor antagonist. Pharmacology Research & Perspectives. 3: e00198
Mercer SP, Roecker AJ, Garson S, et al. (2013) Discovery of 2,5-diarylnicotinamides as selective orexin-2 receptor antagonists (2-SORAs). Bioorganic & Medicinal Chemistry Letters. 23: 6620-4
Coleman PJ, Schreier JD, Cox CD, et al. (2012) Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties. Chemmedchem. 7: 415-24, 337
Layton ME, Kelly MJ, Rodzinak KJ, et al. (2011) Discovery of 3-substituted aminocyclopentanes as potent and orally bioavailable NR2B subtype-selective NMDA antagonists. Acs Chemical Neuroscience. 2: 352-62
Hutson PH, Finger EN, Magliaro BC, et al. (2011) The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents. Neuropharmacology. 61: 665-76
Wood MR, Schirripa KM, Kim JJ, et al. (2010) Novel CGRP receptor antagonists from central amide replacements causing a reversal of preferred chirality. Bioorganic & Medicinal Chemistry Letters. 20: 6827-30
Cox CD, Breslin MJ, Whitman DB, et al. (2010) Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. Journal of Medicinal Chemistry. 53: 5320-32
Stump CA, Bell IM, Bednar RA, et al. (2010) Identification of potent, highly constrained CGRP receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 20: 2572-6
Wood MR, Schirripa KM, Kim JJ, et al. (2009) Novel CGRP receptor antagonists through a design strategy of target simplification with addition of molecular flexibility. Bioorganic & Medicinal Chemistry Letters. 19: 5787-90
McIntyre CJ, McCauley JA, Bednar B, et al. (2009) Synthesis and evaluation of novel tricyclic benzo[4.5]cyclohepta[1.2]pyridine derivatives as NMDA/NR2B antagonists. Bioorganic & Medicinal Chemistry Letters. 19: 5132-5
See more...